$1.97 -0.04 (%) Rigel Pharmaceuticals Inc - NASDAQ

Sep. 30, 2014 | 01:59 PM

Partner Headlines

  1. What You Need to Know About the Roche-InterMune Deal

    Benzinga | Aug. 29, 2014 | 15:51PM EST
  2. InterMune's Roche Deal Sends Peer Group Up

    Benzinga | Aug. 25, 2014 | 11:38AM EST
  3. Morning Market Losers

    Benzinga | Aug. 13, 2014 | 09:51AM EST
  4. Rigel Initiates Phase 3 Studies Of Fostamatinib In ITP

    Benzinga | Jul. 16, 2014 | 08:38AM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Mar. 6, 2014 | 08:11AM EST
  6. Earnings Scheduled For March 4, 2014

    Benzinga | Mar. 4, 2014 | 04:35AM EST
  7. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 5, 2013 | 08:15AM EST
  8. Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints

    Benzinga | Aug. 26, 2013 | 12:02PM EST
  9. Morning Market Losers

    Benzinga | Aug. 26, 2013 | 10:15AM EST
  10. Benzinga's Top Pre-Market Losers

    Benzinga | Aug. 26, 2013 | 08:17AM EST
  11. UPDATE: Rigel Pharma Announces R343 Did Not Meet Primary, Secondary Endpoints in Asthma Trial

    Benzinga | Aug. 26, 2013 | 07:32AM EST
  12. Weekly Preview: Earnings Season Nears The End, China in Focus

    Benzinga | Aug. 2, 2013 | 15:28PM EST
  13. Stocks Open Firm But Reverse Lower On Fiscal Worries

    IBD | Dec. 13, 2012 | 09:32AM EST
  14. Stocks Near Lows In Late Trading; Drug Stocks Sink

    IBD | Dec. 13, 2012 | 08:44AM EST
  15. UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results

    Benzinga | Dec. 13, 2012 | 07:11AM EST
  16. Mid-Day Market Update: Markets Go Red, SolarCity IPO a Success

    Benzinga | Dec. 13, 2012 | 06:54AM EST
  17. UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following Disappointing Phase II Results

    Benzinga | Dec. 13, 2012 | 06:36AM EST
  18. Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint

    Benzinga | Dec. 13, 2012 | 05:12AM EST
  19. Mid-Morning Market Update: Markets Cautiously Rising, Best Buy Boosts

    Benzinga | Dec. 13, 2012 | 03:59AM EST
  20. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 13, 2012 | 03:17AM EST
  21. Morning Market Losers

    Benzinga | Dec. 13, 2012 | 03:02AM EST
  22. Benzinga's Top Pre-Market Losers

    Benzinga | Dec. 13, 2012 | 01:16AM EST
  23. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals

    Benzinga | Nov. 7, 2012 | 03:19AM EST
  24. Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 6, 2012 | 04:35AM EST
  25. UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Rigel Pharmaceuticals

    Benzinga | Oct. 15, 2012 | 05:56AM EST
  26. Rigel Announces Pricing Of 13.685M Share Public Offering at $9.50 per Share

    Benzinga | Oct. 3, 2012 | 03:29AM EST
  27. Rigel Announces Proposed Public Offering Of Common Stock

    Benzinga | Oct. 2, 2012 | 10:11AM EST
  28. Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 7, 2012 | 05:19AM EST
  29. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga | Jul. 10, 2012 | 08:07AM EST
  30. Piper Jaffray Reiterates Overweight on Rigel Pharmaceuticals ahead of Phase III Data

    Benzinga | Mar. 6, 2012 | 02:04AM EST
  31. Benzinga's Top Upgrades

    Benzinga | Feb. 22, 2012 | 01:47AM EST
  32. Financial Breakfast: Morning News Summary for February 22, 2012

    Benzinga | Feb. 22, 2012 | 00:33AM EST
Trading Center